Inflammation company NodThera Ltd. (Cambridge, U.K.) raised £28 million ($37 million) in a tranched series A led by Sofinnova Partners and 5AM Ventures. Epidarex Capital, which founded NodThera in 2016, and F-Prime Capital Partners also participated.
Spun out of Selvita S.A. (Warsaw:SLV), NodThera is developing next-generation NLR family pyrin domain containing 3 (NLRP3; NALP3; CIAS1) inhibitors for inflammation-driven diseases. Although NodThera has not yet named a lead indication, the company plans to pursue inflammatory diseases as well as neurodegenerative diseases and cancers affected by chronic inflammation...
BCIQ Company Profiles
BCIQ Target Profiles
NLR family pyrin domain containing 3 (NLRP3) (NALP3) (CIAS1)